HealthcareServices

Global Polymyositis Market Performance Report: Global Trends 2026–2030

March 5, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the polymyositis market from 2026–2035 with trusted insights from The Business Research Company

What long-term size projections exist for the Polymyositis Market covering 2026–2035?

The polymyositis market has witnessed substantial growth in recent years. It is projected to increase from $1.74 billion in 2025 to $1.85 billion in 2026, reflecting a compound annual growth rate (CAGR) of 6.2%. This historical growth can be attributed to an improved understanding of autoimmune myopathies, the availability of muscle biopsy diagnostics, expanded use of corticosteroids, enhanced hospital diagnostic capabilities, and a rising identification of rare muscle disorders.

The market size for polymyositis is projected to experience robust expansion over the coming years. It is forecast to reach $2.34 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.0%. This growth during the forecast period is attributable to the increasing development of targeted immune therapies, the rising integration of precision diagnostics, a greater utilization of biologics and immunoglobulins, the expansion of personalized treatment strategies, and intensified research into autoimmune disease mechanisms. Significant trends anticipated in the forecast period include the growing application of immunosuppressive therapies, increased adoption of monoclonal antibody treatments, a heightened focus on accurate differential diagnosis, the broadening of advanced diagnostic imaging, and enhanced patient monitoring protocols.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22104&type=smp

Which Drivers Are Impacting The Competitive Landscape Of The Polymyositis Market?

The expanding occurrence of autoimmune conditions is anticipated to fuel the expansion of the polymyositis market in the future. These conditions involve the body’s immune system erroneously targeting its own healthy cells, tissues, or organs, resulting in inflammation and harm. Their rising incidence is linked to specific genetic variations causing an overactive immune response, heightening individuals’ vulnerability to self-tissue attacks. This genetic predisposition, coupled with environmental factors like infections, stress, and lifestyle choices, contributes to the growing number of autoimmune cases. Polymyositis itself aids in comprehending autoimmune diseases by illustrating how immune system irregularities cause muscle inflammation, thereby providing valuable insights into underlying mechanisms and potential therapies for associated conditions. For example, in February 2024, data from Arthritis Australia, an Australia-based charitable not-for-profit organisation advocating for people with arthritis and musculoskeletal conditions, indicated that by 2025, roughly 562,378 Australians will be affected by rheumatoid arthritis (RA), comprising 14% of the overall arthritis demographic. Consequently, the growing prevalence of autoimmune diseases is a key driver for the polymyositis market.

What Segments Are Identified Within The Structure Of The Polymyositis Market?

The polymyositis market covered in this report is segmented –

1) By Type: Idiopathic Polymyositis, Dermatomyositis, Inclusion Body Myositis, Overlapping Myositis Syndromes

2) By Diagnosis: Physical Examination, Muscle Biopsy, Electromyography (EMG), Blood Tests, Magnetic Resonance Imaging (MRI)

3) By Treatment: Immunosuppressant, Immunoglobulins, Corticosteroids, Alkylating agents, Monoclonal Antibodies

4) By Distribution Channel: Offline, Online

5) By End User: Hospital pharmacy, Online pharmacy, Retail pharmacy

Subsegments:

1) By Idiopathic Polymyositis: Immune-Mediated Polymyositis, Virus-Associated Polymyositis

2) By Dermatomyositis: Classic Dermatomyositis, Amyopathic Dermatomyositis, Juvenile Dermatomyositis

3) By Inclusion Body Myositis: Sporadic Inclusion Body Myositis, Hereditary Inclusion Body Myopathy

4) By Overlapping Myositis Syndromes:Polymyositis with Systemic Lupus Erythematosus (SLE), Polymyositis with Rheumatoid Arthritis (RA), Polymyositis with Systemic Sclerosis, Polymyositis with Mixed Connective Tissue Disease (MCTD)

What Upcoming Trends Are Likely To Define The Future Path Of The Polymyositis Market?

Companies operating within the polymyositis market are primarily focused on developing innovative therapies, such as stem cell treatments, to improve treatment efficacy and slow the progression of the disease. Stem cell therapy involves the application of umbilical cord-derived stem cells for regenerative medical purposes. These stem cells exhibit powerful immunomodulatory and anti-inflammatory properties, making them a viable option for treating autoimmune conditions like polymyositis. For example, in December 2024, RESTEM, a US-based clinical-stage biotechnology company, received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for its stem cell program that utilizes umbilical cord outer lining stem cells (ULSCs). This program employs umbilical cord outer lining stem cells to treat polymyositis and Dermatomyositis by regulating the immune system and reducing muscle inflammation. Early trials have demonstrated promising safety and efficacy for this therapy, with the potential to decrease steroid dependency.

Which Leading Companies Dominate The Polymyositis Market Share?

Major companies operating in the polymyositis market are Pfizer Inc., F Hoffmann La Roche AG, Bristol Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Merck & Co. Inc., C H Boehringer Sohn AG & Co. KG, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Fresenius SE & Co. KGaA, UCB S.A., Teva Pharmaceuticals USA Inc., Kezar Life Sciences Inc., Argenx SE, Mallinckrodt Pharmaceuticals plc, Mitsubishi Tanabe Pharma Corporation, Sanofi S.A., AbbVie Inc., Eli Lilly and Company, Janssen Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., CSL Behring

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/polymyositis-global-market-report

How Does The Polymyositis Market Perform Across Major Global Regions?

North America was the largest region in the polymyositis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the polymyositis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Polymyositis Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=22104&type=smp

Browse Through More Reports Similar to the Global Polymyositis Market 2026, By The Business Research Company

Pheochromocytoma Market Report 2026

https://www.thebusinessresearchcompany.com/report/pheochromocytoma-global-market-report

Pericarditis Market Report 2026

https://www.thebusinessresearchcompany.com/report/pericarditis-global-market-report

Interstitial Cystitis Market Report 2026

https://www.thebusinessresearchcompany.com/report/interstitial-cystitis-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795